# Vaccine Therapy and OPT-821 or OPT-821 Alone in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer in Complete Remission

> **NCT00693342** · PHASE3 · WITHDRAWN · sponsor: **Gynecologic Oncology Group**

## Conditions studied

- Fallopian Tube Cancer
- Ovarian Cancer
- Primary Peritoneal Cavity Cancer

## Interventions

- **BIOLOGICAL:** immunological adjuvant OPT-821
- **BIOLOGICAL:** polyvalent antigen-KLH conjugate vaccine

## Key facts

- **NCT ID:** NCT00693342
- **Lead sponsor:** Gynecologic Oncology Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Never opened to accrual, a GOG working number, not developed into a clinical trial.
- **Last updated:** 2020-02-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00693342

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00693342, "Vaccine Therapy and OPT-821 or OPT-821 Alone in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer in Complete Remission". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00693342. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*